Dataset from Multicentre, Single-arm, Open Label Clinical Trial Intended to Provide Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen and to Document Safety of Cabazitaxel in These Patients

The purpose of this study is to allow patients similar to that evaluated in the TROPIC trial
(NCT00417079), and Investigators access to cabazitaxel for the management of metastatic
Hormone Refractory Prostate Cancer (mHRPC) in those patients who have progressed during or
after docetaxel and to document the overall safety of cabazitaxel in these patients.

Please note that in each country, patient recruitment will end when cabazitaxel becomes
commercially available.